Page last updated: 2024-11-11

oxotremorine sesquifumarate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6436473
CHEMBL ID1551988
MeSH IDM0141607

Synonyms (33)

Synonym
2-pyrrolidinone, 1-(4-(1-pyrrolidinyl)-2-butynyl)-, fumarate (2:3)
bis(1-(4-(pyrrolidin-1-yl)but-2-ynyl)pyrrolidin-2-one) trifumarate
2-pyrrolidinone, 1-(4-(1-pyrrolidinyl)-2-butynyl)-, (e)-2-butenedioate (2:3)
oxotremorine fumarate (2:3)
einecs 241-388-3
2-pyrrolidinone, 1-(4-(1-pyrrolidinyl)-2-butynyl)-, sesquifumarate
1-(n-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinone sesquifumarate
HMS3266J20
EU-0100914
oxotremorine sesquifumarate salt, >=98% (hplc), solid
oxotremorine sesquifumarate
NCGC00094225-01
oxotremorine sesquifumarate salt
O 9126
17360-35-9
1-[4-(1-pyrrolidinyl)-2-butynyl]-2-pyrrolidinone sesquifumarate
HMS3262H10
LP00914
CCG-222218
tox21_500914
NCGC00261599-01
1-(4-(pyrrolidin-1-yl)but-2-yn-1-yl)pyrrolidin-2-one sesquifumarate
CHEMBL1551988
AKOS024458667
tris((2e)-but-2-enedioic acid); bis(1-[4-(pyrrolidin-1-yl)but-2-yn-1-yl]pyrrolidin-2-one)
AS-73701
oxotremorine ses-quifumarate salt
HMS3675P09
(e)-but-2-enedioic acid;1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one
HMS3411P09
DTXSID201017212
oxotremorinesesquifumarate
2-pyrrolidinone, 1-(4-(1-pyrrolidinyl)-2-butynyl)-, (e)-2-butenedioate (2:3) (9ci)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.68580.100020.879379.4328AID588453
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.02510.540617.639296.1227AID2364; AID2528
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's3 (17.65)18.2507
2000's4 (23.53)29.6817
2010's3 (17.65)24.3611
2020's3 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]